Memo Therapeutics AG

📍 Schlieren, Switzerland🗓 Founded 2012👥 44 employees💰 Last funded Oct 2024
Biotechnology Research🌐 memo-therapeutics.com
Website LinkedIn
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.
5
Total investors
0
Early stage
1
Mid stage
3
Late stage
2012
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
4
Germany
1
Investor activity2015–2024 · investors recorded per year
20151201822020120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Memo Therapeutics AG?
Memo Therapeutics AG has 5 investors on record on gritt.io, 1 mid-stage and 3 late-stage investors.
When did Memo Therapeutics AG last raise funding?
The most recent investment in Memo Therapeutics AG recorded on gritt.io was in October 2024.
When was Memo Therapeutics AG founded?
Memo Therapeutics AG was founded in 2012.
What industry is Memo Therapeutics AG in?
Memo Therapeutics AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Memo Therapeutics AG based?
Memo Therapeutics AG is headquartered in Schlieren, Switzerland.